Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $21,577.40 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider Lorenz Muller sold 11,180 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $21,577.40. Following the completion of the sale, the insider owned 205,406 shares of the company’s stock, valued at $396,433.58. This trade represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Lorenz Muller also recently made the following trade(s):

• On Monday, December 15th, Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total value of $124,273.12.

Milestone Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ MIST traded down $0.07 during trading on Wednesday, reaching $1.94. The stock had a trading volume of 1,697,941 shares, compared to its average volume of 3,110,069. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The company has a market cap of $165.23 million, a P/E ratio of -2.37 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The business’s 50-day moving average price is $2.23 and its 200-day moving average price is $1.96.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. On average, equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

MIST has been the topic of a number of research reports. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Key Milestone Pharmaceuticals News

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Institutional Trading of Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Simplify Asset Management Inc. boosted its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares during the last quarter. Bay Rivers Group boosted its holdings in Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after purchasing an additional 12,170 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals in the third quarter valued at approximately $1,333,000. Finally, Aptus Capital Advisors LLC acquired a new stake in Milestone Pharmaceuticals during the third quarter worth approximately $420,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.